Avoid prophylactic platelet transfusions in asymptomatic thrombocytopenic patients with chronic bone marrow failure who are not receiving intensive chemotherapy. Exercise particular restraint in the end-of-life phase Avoid advanced hematological diagnostics—such as cytogenetics, molecular pathology, and flow cytometry—in patients where potential findings would not have therapeutic consequences, for example due to advanced age, frailty or comorbidity Avoid routine ordering of laboratory test panels in hospitalized patients without a clear indication Avoid whole-body MRI in patients with mild to severe frailty (Clinical Frailty Scale, CFS 5–9) with smouldering multiple myeloma Restraint performing bone marrow examinations in (elderly) patients living with mild to severe frailty (CFS 5–9) when a potential hematological diagnosis would not alter treatment or follow-up Avoid recommending routine follow-up visits for patients without treatment options and who are not receiving active treatment Perform a systematic frailty assessment before initiating treatment and when reassessing treatment in patients above 70-75 years Conduct advance care planning with shared decision-making, particularly in patients for whom hematological treatment has uncertain or limited expected benefit, where there is a risk of adverse effects and complications, in patients with...